RASAZILECT rasagiline mesilate1 mg tablets, bottle

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

rasagiline mesilate, Quantity: 1.56 mg

Available from:

Arrotex Pharmaceuticals Pty Ltd

Pharmaceutical form:

Tablet, uncoated

Composition:

Excipient Ingredients: purified talc; microcrystalline cellulose; citric acid; silicon dioxide; pregelatinised maize starch; stearic acid; maize starch

Administration route:

Oral

Units in package:

30

Prescription type:

(S4) Prescription Only Medicine

Therapeutic indications:

Rasagiline is indicated for the symptomatic treatment of idiopathic Parkinsons disease (PD) as monotherapy (without concomitant levodopa/decarboxylase inhibitor therapy) or as adjunct therapy (with concomitant levodopa/decarboxylase inhibitor therapy).

Product summary:

Visual Identification: White to off-white, round, flat bevelled tablets debossed with "C13" on one side and plain on the other side.; Container Type: Bottle; Container Material: HDPE; Container Life Time: 30 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

Authorization status:

Registered

Authorization date:

2018-01-23